FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

NCT01913639 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

DRUG: Regorafenib
DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: Oxaliplatin

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]